JP7028953B2 - Ｃｅａ、ｍｕｃ１およびｔｅｒｔを含む免疫原性組成物 - Google Patents

Ｃｅａ、ｍｕｃ１およびｔｅｒｔを含む免疫原性組成物 Download PDF

Info

Publication number
JP7028953B2
JP7028953B2 JP2020500687A JP2020500687A JP7028953B2 JP 7028953 B2 JP7028953 B2 JP 7028953B2 JP 2020500687 A JP2020500687 A JP 2020500687A JP 2020500687 A JP2020500687 A JP 2020500687A JP 7028953 B2 JP7028953 B2 JP 7028953B2
Authority
JP
Japan
Prior art keywords
seq
nucleotide sequence
amino acid
polypeptide
immunogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2020500687A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020526202A5 (enExample
JP2020526202A (ja
Inventor
ジョン ビンダー ジョセフ
キム チョ ヘレン
ジェイソン コックル ポール
ジョン ファルコナー デレク
グル シラダナハリー
マルセラ アンドレア マルティニック マリアン
Original Assignee
ファイザー・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイザー・インク filed Critical ファイザー・インク
Publication of JP2020526202A publication Critical patent/JP2020526202A/ja
Publication of JP2020526202A5 publication Critical patent/JP2020526202A5/ja
Priority to JP2021175480A priority Critical patent/JP2022031653A/ja
Application granted granted Critical
Publication of JP7028953B2 publication Critical patent/JP7028953B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020500687A 2017-07-11 2018-07-03 Ｃｅａ、ｍｕｃ１およびｔｅｒｔを含む免疫原性組成物 Expired - Fee Related JP7028953B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021175480A JP2022031653A (ja) 2017-07-11 2021-10-27 Ｃｅａ、ｍｕｃ１およびｔｅｒｔを含む免疫原性組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762531227P 2017-07-11 2017-07-11
US62/531,227 2017-07-11
US201862682044P 2018-06-07 2018-06-07
US62/682,044 2018-06-07
PCT/IB2018/054926 WO2019012371A1 (en) 2017-07-11 2018-07-03 IMMUNOGENIC COMPOSITIONS COMPRISING CEA MUC1 AND TERT

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021175480A Division JP2022031653A (ja) 2017-07-11 2021-10-27 Ｃｅａ、ｍｕｃ１およびｔｅｒｔを含む免疫原性組成物

Publications (3)

Publication Number Publication Date
JP2020526202A JP2020526202A (ja) 2020-08-31
JP2020526202A5 JP2020526202A5 (enExample) 2021-03-25
JP7028953B2 true JP7028953B2 (ja) 2022-03-02

Family

ID=63720720

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020500687A Expired - Fee Related JP7028953B2 (ja) 2017-07-11 2018-07-03 Ｃｅａ、ｍｕｃ１およびｔｅｒｔを含む免疫原性組成物
JP2021175480A Pending JP2022031653A (ja) 2017-07-11 2021-10-27 Ｃｅａ、ｍｕｃ１およびｔｅｒｔを含む免疫原性組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021175480A Pending JP2022031653A (ja) 2017-07-11 2021-10-27 Ｃｅａ、ｍｕｃ１およびｔｅｒｔを含む免疫原性組成物

Country Status (16)

Country Link
US (1) US20190016775A1 (enExample)
EP (1) EP3651792A1 (enExample)
JP (2) JP7028953B2 (enExample)
KR (1) KR20200027551A (enExample)
CN (1) CN111065408A (enExample)
AU (1) AU2018300295A1 (enExample)
BR (1) BR112020000413A2 (enExample)
CA (1) CA3069363A1 (enExample)
CO (1) CO2020000231A2 (enExample)
IL (1) IL271917A (enExample)
PE (1) PE20200613A1 (enExample)
PH (1) PH12020500087A1 (enExample)
RU (1) RU2020100072A (enExample)
SG (1) SG11202000197PA (enExample)
TW (1) TW201920674A (enExample)
WO (1) WO2019012371A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102020201219A1 (de) 2020-01-31 2021-08-05 United Initiators Gmbh Transport- und Lagerbehälter für Peroxide
AU2021294322A1 (en) * 2020-06-26 2023-02-02 National Breast Cancer Coalition Breast cancer vaccine
CN116635525A (zh) * 2020-08-21 2023-08-22 北京大学 环状rna疫苗及其使用方法
CN112552380B (zh) * 2020-12-10 2021-12-24 武汉博沃生物科技有限公司 一种SARS-CoV-2病毒的免疫原及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050059624A1 (en) 2001-12-19 2005-03-17 Ingmar Hoerr Application of mRNA for use as a therapeutic against tumour diseases
WO2016112195A1 (en) 2015-01-09 2016-07-14 Etubics Corporation Methods and compositions for combination immunotherapy

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5288641A (en) 1984-06-04 1994-02-22 Arch Development Corporation Herpes Simplex virus as a vector
CA1341482C (en) 1984-10-31 2005-05-10 Paul A. Luciw Process for preparing fragments of aids-associated retroviruses
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US5091309A (en) 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
US5716826A (en) 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
US5591624A (en) 1988-03-21 1997-01-07 Chiron Viagene, Inc. Retroviral packaging cell lines
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5817491A (en) 1990-09-21 1998-10-06 The Regents Of The University Of California VSV G pseusdotyped retroviral vectors
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US6962790B1 (en) 1998-09-23 2005-11-08 University Of Massachusetts Medical Center Predictive assay for immune response
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
TWI228718B (en) 2001-11-05 2005-03-01 Tdk Corp Manufacturing method and device of mold plate for information medium
JP4814800B2 (ja) 2004-01-23 2011-11-16 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー チンパンジーアデノウイルスワクチン担体
CN101522706B (zh) * 2006-10-12 2013-09-04 P.安杰莱蒂分子生物学研究所 端粒酶逆转录酶融合蛋白、编码它的核苷酸以及其用途
CA3012229C (en) 2008-07-08 2020-11-10 Incyte Holdings Corporation 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
HUE039908T2 (hu) 2009-02-02 2019-02-28 Glaxosmithkline Biologicals Sa Majom adenovírusból származó nukleinsav- és aminosav-szekvenciák, azt tartalmazó vektorok és alkalmazásuk
US9128725B2 (en) 2012-05-04 2015-09-08 Apple Inc. Load-store dependency predictor content management
PT3199552T (pt) * 2012-11-20 2020-03-25 Sanofi Sa Anticorpos anti-ceacam5 e suas utilizações
JP2014161283A (ja) * 2013-02-26 2014-09-08 Shizuoka Prefecture Ｃｅａｃａｍ５遺伝子のスプライシングバリアント
AU2014310932B2 (en) * 2013-08-21 2019-06-06 CureVac SE Composition and vaccine for treating lung cancer
CA2928542A1 (en) 2013-10-28 2015-05-07 Piramal Enterprises Limited Herbal composition, process for its preparation and use thereof
EP3524262A1 (en) 2013-11-01 2019-08-14 Pfizer Inc Vectors for expression of prostate-associated antigens
EA201650031A1 (ru) 2014-05-15 2017-06-30 Итеос Терапьютик Производные пирролидин-2,5-диона, фармацевтические композиции и способы применения в качестве ингибиторов ido1
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050059624A1 (en) 2001-12-19 2005-03-17 Ingmar Hoerr Application of mRNA for use as a therapeutic against tumour diseases
WO2016112195A1 (en) 2015-01-09 2016-07-14 Etubics Corporation Methods and compositions for combination immunotherapy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Clin. Cancer Res., 2008, Vol. 14, No. 10, pp. 3060-3069
Mol. Ther., 2011, Vol. 19, No. 5, pp. 990-999
Oncotarget, 2015, Vol. 6, No. 31, pp. 31344-31359

Also Published As

Publication number Publication date
BR112020000413A2 (pt) 2020-07-21
CN111065408A (zh) 2020-04-24
AU2018300295A1 (en) 2020-01-23
RU2020100072A3 (enExample) 2021-08-11
JP2022031653A (ja) 2022-02-22
CA3069363A1 (en) 2019-01-17
TW201920674A (zh) 2019-06-01
PH12020500087A1 (en) 2020-09-14
EP3651792A1 (en) 2020-05-20
KR20200027551A (ko) 2020-03-12
CO2020000231A2 (es) 2020-01-17
WO2019012371A1 (en) 2019-01-17
SG11202000197PA (en) 2020-02-27
RU2020100072A (ru) 2021-08-11
US20190016775A1 (en) 2019-01-17
IL271917A (en) 2020-02-27
JP2020526202A (ja) 2020-08-31
PE20200613A1 (es) 2020-03-11

Similar Documents

Publication Publication Date Title
JP7014764B2 (ja) 前立腺関連抗原を発現させるためのベクター
JP2022031653A (ja) Ｃｅａ、ｍｕｃ１およびｔｅｒｔを含む免疫原性組成物
US20220323558A1 (en) Cancer vaccines
HK1224563A1 (en) Vectors for expression of prostate-associated antigens
US20250049903A1 (en) Therapy for Modulating Immune Response with Recombinant MVA Encoding IL-12

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210210

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20210210

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20210309

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210511

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210608

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210831

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211027

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20211027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211028

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20211122

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20211213

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220202

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220217

R150 Certificate of patent or registration of utility model

Ref document number: 7028953

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees